Skip to main content
Erschienen in: Acta Neuropathologica 2/2019

13.11.2018 | Original Paper

The metalloprotease ADAMTS4 generates N-truncated Aβ4–x species and marks oligodendrocytes as a source of amyloidogenic peptides in Alzheimer’s disease

verfasst von: Susanne Walter, Thorsten Jumpertz, Melanie Hüttenrauch, Isabella Ogorek, Hermeto Gerber, Steffen E. Storck, Silvia Zampar, Mitko Dimitrov, Sandra Lehmann, Klaudia Lepka, Carsten Berndt, Jens Wiltfang, Christoph Becker-Pauly, Dirk Beher, Claus U. Pietrzik, Patrick C. Fraering, Oliver Wirths, Sascha Weggen

Erschienen in: Acta Neuropathologica | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Abstract

Brain accumulation and aggregation of amyloid-β (Aβ) peptides is a critical step in the pathogenesis of Alzheimer’s disease (AD). Full-length Aβ peptides (mainly Aβ1–40 and Aβ1–42) are produced through sequential proteolytic cleavage of the amyloid precursor protein (APP) by β- and γ-secretases. However, studies of autopsy brain samples from AD patients have demonstrated that a large fraction of insoluble Aβ peptides are truncated at the N-terminus, with Aβ4–x peptides being particularly abundant. Aβ4–x peptides are highly aggregation prone, but their origin and any proteases involved in their generation are unknown. We have identified a recognition site for the secreted metalloprotease ADAMTS4 (a disintegrin and metalloproteinase with thrombospondin motifs 4) in the Aβ peptide sequence, which facilitates Aβ4–x peptide generation. Inducible overexpression of ADAMTS4 in HEK293 cells resulted in the secretion of Aβ4–40 but unchanged levels of Aβ1–x peptides. In the 5xFAD mouse model of amyloidosis, Aβ4–x peptides were present not only in amyloid plaque cores and vessel walls, but also in white matter structures co-localized with axonal APP. In the ADAMTS4−/− knockout background, Aβ4–40 levels were reduced confirming a pivotal role of ADAMTS4 in vivo. Surprisingly, in the adult murine brain, ADAMTS4 was exclusively expressed in oligodendrocytes. Cultured oligodendrocytes secreted a variety of Aβ species, but Aβ4–40 peptides were absent in cultures derived from ADAMTS4−/− mice indicating that the enzyme was essential for Aβ4–x production in this cell type. These findings establish an enzymatic mechanism for the generation of Aβ4–x peptides. They further identify oligodendrocytes as a source of these highly amyloidogenic Aβ peptides.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Association Alzheimer’s (2016) 2016 Alzheimer’s disease facts and figures. Alzheimers Dement 12:459–509CrossRef Association Alzheimer’s (2016) 2016 Alzheimer’s disease facts and figures. Alzheimers Dement 12:459–509CrossRef
4.
5.
Zurück zum Zitat Baumann N, Pham-Dinh D (2001) Biology of oligodendrocyte and myelin in the mammalian central nervous system. Physiol Rev 81:871–927CrossRefPubMed Baumann N, Pham-Dinh D (2001) Biology of oligodendrocyte and myelin in the mammalian central nervous system. Physiol Rev 81:871–927CrossRefPubMed
8.
Zurück zum Zitat Brockhaus M, Grunberg J, Rohrig S, Loetscher H, Wittenburg N, Baumeister R et al (1998) Caspase-mediated cleavage is not required for the activity of presenilins in amyloidogenesis and NOTCH signaling. NeuroReport 9:1481–1486CrossRefPubMed Brockhaus M, Grunberg J, Rohrig S, Loetscher H, Wittenburg N, Baumeister R et al (1998) Caspase-mediated cleavage is not required for the activity of presenilins in amyloidogenesis and NOTCH signaling. NeuroReport 9:1481–1486CrossRefPubMed
20.
Zurück zum Zitat Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, Trono D et al (1998) A third-generation lentivirus vector with a conditional packaging system. J Virol 72:8463–8471PubMedPubMedCentral Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, Trono D et al (1998) A third-generation lentivirus vector with a conditional packaging system. J Virol 72:8463–8471PubMedPubMedCentral
23.
Zurück zum Zitat Haddock G, Cross AK, Plumb J, Surr J, Buttle DJ, Bunning RA et al (2006) Expression of ADAMTS-1, -4, -5 and TIMP-3 in normal and multiple sclerosis CNS white matter. Mult Scler 12:386–396CrossRefPubMed Haddock G, Cross AK, Plumb J, Surr J, Buttle DJ, Bunning RA et al (2006) Expression of ADAMTS-1, -4, -5 and TIMP-3 in normal and multiple sclerosis CNS white matter. Mult Scler 12:386–396CrossRefPubMed
26.
Zurück zum Zitat Hersh LB, Rodgers DW (2008) Neprilysin and amyloid beta peptide degradation. Curr Alzheimer Res 5:225–231CrossRefPubMed Hersh LB, Rodgers DW (2008) Neprilysin and amyloid beta peptide degradation. Curr Alzheimer Res 5:225–231CrossRefPubMed
27.
28.
Zurück zum Zitat Howell S, Nalbantoglu J, Crine P (1995) Neutral endopeptidase can hydrolyze beta-amyloid(1-40) but shows no effect on beta-amyloid precursor protein metabolism. Peptides 16:647–652CrossRefPubMed Howell S, Nalbantoglu J, Crine P (1995) Neutral endopeptidase can hydrolyze beta-amyloid(1-40) but shows no effect on beta-amyloid precursor protein metabolism. Peptides 16:647–652CrossRefPubMed
30.
Zurück zum Zitat Iwata N, Tsubuki S, Takaki Y, Watanabe K, Sekiguchi M, Hosoki E et al (2000) Identification of the major Abeta1-42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition. Nat Med 6:143–150. https://doi.org/10.1038/72237 CrossRefPubMed Iwata N, Tsubuki S, Takaki Y, Watanabe K, Sekiguchi M, Hosoki E et al (2000) Identification of the major Abeta1-42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition. Nat Med 6:143–150. https://​doi.​org/​10.​1038/​72237 CrossRefPubMed
31.
Zurück zum Zitat Jansen I, Savage J, Watanabe K, Bryois J, Williams D, Steinberg S et al (2018) Genetic meta-analysis identifies 9 novel loci and functional pathways for Alzheimers disease risk. bioRxiv 258533; doi: https://doi.org/10.1101/258533 Jansen I, Savage J, Watanabe K, Bryois J, Williams D, Steinberg S et al (2018) Genetic meta-analysis identifies 9 novel loci and functional pathways for Alzheimers disease risk. bioRxiv 258533; doi: https://​doi.​org/​10.​1101/​258533
36.
Zurück zum Zitat Kalback W, Watson MD, Kokjohn TA, Kuo YM, Weiss N, Luehrs DC et al (2002) APP transgenic mice Tg2576 accumulate Abeta peptides that are distinct from the chemically modified and insoluble peptides deposited in Alzheimer’s disease senile plaques. Biochemistry 41:922–928CrossRefPubMed Kalback W, Watson MD, Kokjohn TA, Kuo YM, Weiss N, Luehrs DC et al (2002) APP transgenic mice Tg2576 accumulate Abeta peptides that are distinct from the chemically modified and insoluble peptides deposited in Alzheimer’s disease senile plaques. Biochemistry 41:922–928CrossRefPubMed
48.
Zurück zum Zitat Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K (1985) Amyloid plaque core protein in Alzheimer disease and down syndrome. Proc Natl Acad Sci U S A 82:4245–4249CrossRefPubMedPubMedCentral Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K (1985) Amyloid plaque core protein in Alzheimer disease and down syndrome. Proc Natl Acad Sci U S A 82:4245–4249CrossRefPubMedPubMedCentral
54.
Zurück zum Zitat Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J et al (2006) Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer’s disease mutations: potential factors in amyloid plaque formation. J Neurosci 26:10129–10140CrossRefPubMedPubMedCentral Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J et al (2006) Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer’s disease mutations: potential factors in amyloid plaque formation. J Neurosci 26:10129–10140CrossRefPubMedPubMedCentral
56.
Zurück zum Zitat Pike CJ, Overman MJ, Cotman CW (1995) Amino-terminal deletions enhance aggregation of beta-amyloid peptides in vitro. J Biol Chem 270:23895–23898CrossRefPubMed Pike CJ, Overman MJ, Cotman CW (1995) Amino-terminal deletions enhance aggregation of beta-amyloid peptides in vitro. J Biol Chem 270:23895–23898CrossRefPubMed
59.
65.
Zurück zum Zitat Roher AE, Weiss N, Kokjohn TA, Kuo YM, Kalback W, Anthony J et al (2002) Increased A beta peptides and reduced cholesterol and myelin proteins characterize white matter degeneration in Alzheimer’s disease. Biochemistry 41:11080–11090CrossRefPubMed Roher AE, Weiss N, Kokjohn TA, Kuo YM, Kalback W, Anthony J et al (2002) Increased A beta peptides and reduced cholesterol and myelin proteins characterize white matter degeneration in Alzheimer’s disease. Biochemistry 41:11080–11090CrossRefPubMed
68.
Zurück zum Zitat Sergeant N, Bombois S, Ghestem A, Drobecq H, Kostanjevecki V, Missiaen C et al (2003) Truncated beta-amyloid peptide species in pre-clinical Alzheimer’s disease as new targets for the vaccination approach. J Neurochem 85:1581–1591CrossRefPubMed Sergeant N, Bombois S, Ghestem A, Drobecq H, Kostanjevecki V, Missiaen C et al (2003) Truncated beta-amyloid peptide species in pre-clinical Alzheimer’s disease as new targets for the vaccination approach. J Neurochem 85:1581–1591CrossRefPubMed
73.
Zurück zum Zitat Tortorella MD, Burn TC, Pratta MA, Abbaszade I, Hollis JM, Liu R et al (1999) Purification and cloning of aggrecanase-1: a member of the ADAMTS family of proteins. Science 284:1664–1666CrossRefPubMed Tortorella MD, Burn TC, Pratta MA, Abbaszade I, Hollis JM, Liu R et al (1999) Purification and cloning of aggrecanase-1: a member of the ADAMTS family of proteins. Science 284:1664–1666CrossRefPubMed
74.
Zurück zum Zitat Tortorella MD, Malfait F, Barve RA, Shieh HS, Malfait AM (2009) A review of the ADAMTS family, pharmaceutical targets of the future. Curr Pharm Des 15:2359–2374CrossRefPubMed Tortorella MD, Malfait F, Barve RA, Shieh HS, Malfait AM (2009) A review of the ADAMTS family, pharmaceutical targets of the future. Curr Pharm Des 15:2359–2374CrossRefPubMed
77.
Zurück zum Zitat Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, Pietrzik CU et al (2001) A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 414:212–216CrossRefPubMed Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, Pietrzik CU et al (2001) A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 414:212–216CrossRefPubMed
80.
81.
Zurück zum Zitat Yamamoto K, Owen K, Parker AE, Scilabra SD, Dudhia J, Strickland DK et al (2014) Low density lipoprotein receptor-related protein 1 (LRP1)-mediated endocytic clearance of a disintegrin and metalloproteinase with thrombospondin motifs-4 (ADAMTS-4): functional differences of non-catalytic domains of ADAMTS-4 and ADAMTS-5 in LRP1 binding. J Biol Chem 289:6462–6474. https://doi.org/10.1074/jbc.M113.545376 CrossRefPubMedPubMedCentral Yamamoto K, Owen K, Parker AE, Scilabra SD, Dudhia J, Strickland DK et al (2014) Low density lipoprotein receptor-related protein 1 (LRP1)-mediated endocytic clearance of a disintegrin and metalloproteinase with thrombospondin motifs-4 (ADAMTS-4): functional differences of non-catalytic domains of ADAMTS-4 and ADAMTS-5 in LRP1 binding. J Biol Chem 289:6462–6474. https://​doi.​org/​10.​1074/​jbc.​M113.​545376 CrossRefPubMedPubMedCentral
Metadaten
Titel
The metalloprotease ADAMTS4 generates N-truncated Aβ4–x species and marks oligodendrocytes as a source of amyloidogenic peptides in Alzheimer’s disease
verfasst von
Susanne Walter
Thorsten Jumpertz
Melanie Hüttenrauch
Isabella Ogorek
Hermeto Gerber
Steffen E. Storck
Silvia Zampar
Mitko Dimitrov
Sandra Lehmann
Klaudia Lepka
Carsten Berndt
Jens Wiltfang
Christoph Becker-Pauly
Dirk Beher
Claus U. Pietrzik
Patrick C. Fraering
Oliver Wirths
Sascha Weggen
Publikationsdatum
13.11.2018
Verlag
Springer Berlin Heidelberg
Erschienen in
Acta Neuropathologica / Ausgabe 2/2019
Print ISSN: 0001-6322
Elektronische ISSN: 1432-0533
DOI
https://doi.org/10.1007/s00401-018-1929-5

Weitere Artikel der Ausgabe 2/2019

Acta Neuropathologica 2/2019 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.